AIM AIM ImmunoTech

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

As part of the conference, members of management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the Company’s Maxim Growth Summit presentation slide deck, please visit the on .

For more information and a complete agenda of the Maxim Growth Summit, please visit .

About Maxim Group

Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The independent and employee-owned firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA, SIPC, and NASDAQ. To learn more about Maxim Group LLC, visit maximgrp.com.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials. Ampligen is currently being studied in collaboration with AstraZeneca in combining AIM’s drug with durvalumab for the treatment of metastatic pancreatic cancer.

For more information, please visit  and connect with the Company on , , and .



Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
EN
20/10/2025

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent...

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. The paten...

March 18, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Closing of its Rights Offering

AIM ImmunoTech Announces Closing of its Rights Offering OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today the closing of its previously announced rights offering (the “Rights Offering”). The Rights Offering resulted in total subscriptions of approximately $1.8 million. Each right ent...

March 7, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rig...

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced the preliminary results of its previously announced rights offering (the “Rights Offering”) which expired a...

March 4, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clin...

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3 clinical trial in the use of the Company’s drug Ampligen in the treatment of late-stage pancreatic cancer. AIM CEO Thomas K. Equels states: “The ongoing Phase 2 DURIPANC clinical trial of Ampligen and AstraZeneca’s durvalum...

March 2, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date a...

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”). Each subscription right...

February 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch